SODIUM LACTATE, L-

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C3H5O3.Na
Molecular Weight	112.0598
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].C[C@H](O)C([O-])=O

InChI

InChIKey=NGSFWBMYFKHRBD-DKWTVANSSA-M

InChI=1S/C3H6O3.Na/c1-2(4)3(5)6;/h2,4H,1H3,(H,5,6);/q;+1/p-1/t2-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C3H5O3
Molecular Weight	89.07
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C61808 | https://acutecaretesting.org/en/articles/l-lactate-and-d-lactate-clinical-significance-of-the-difference | https://secure.megazyme.com/files/Booklet/K-DLATE_DATA.pdf | https://aidsinfo.nih.gov/drugs/403/poly-l-lactic-acid/0/professional | https://www.ncbi.nlm.nih.gov/pubmed/16703779

Lactic Acid, L- (L-lactic acid, L-lactate) is the levorotatory isomer of lactic acid, the biologically active isoform in humans. Lactic acid or lactate is produced during fermentation from pyruvate by lactate dehydrogenase. Lactate dehydrogenase is isomer-specific so that production and metabolism of D-lactate require D-LDH and L-lactate requires L-LDH. Mammalian cells only contain L-LDH so that in humans the lactate produced is almost exclusively L-lactate. Carbohydrate-fermenting bacterial species (e.g. lactobacillus spp) have by contrast both enzymes and therefore the capacity to produce both D-lactate and L-lactate. L-lactic acid is the primary agonist of hydroxycarboxylic acid receptor 1 (HCA1), which is a Gi/o-coupled G protein-coupled receptor (GPCR). Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can be used to restore volume and stimulate collagen formation gradually. It is FDA-approved for the correction of facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients. It is FDA-approved for use in immunocompetent people for the correction of nasolabial fold deficiencies and other facial wrinkles. It has been used off-label to enhance the cheeks, hands, neck, thighs, gluteal enhancement and chest wall deformities, such as pectus excavatum or thoracic deformities secondary to surgical procedures.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hydroxycarboxylic acid receptor 1 3 Target ID: Q9BXC0 Gene ID: 27198.0 Gene Symbol: HCAR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21454438	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Renal replacement therapy 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021703s018,207026s004lbl.pdf	Palliative		Approved 8429	PRISMASOL Approved Use PRISMASOL solution is indicated as a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialyzable substances. Launch Date 2006

PubMed

Title	Date	PubMed
High resolution 1H n.m.r. studies of vertebrate blood and plasma.	1983 Jun 1	6411064
1H NMR characterization of normal human cerebrospinal fluid and the detection of methylmalonic acid in a vitamin B12 deficient patient.	1991 Aug	1931558
Malignant ventricular tachycardia during propafenone treatment in a child with junctional automatic tachycardia: effectiveness of intravenous molar sodium lactate.	1991 May	1712954
Physiology and pathophysiology of organic acids in cerebrospinal fluid.	1993	8412012
Lactate and pyruvate concentrations in capillary blood from newborns.	1994 Sep	7819686
Intracellular flux analysis applied to the effect of dissolved oxygen on hybridomas.	1995 Dec	8579834
Standardized method for high-resolution 1H-NMR of cerebrospinal fluid.	1995 May	7729054
Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients.	1998	9693263
Paraquat-induced renal injury studied by 1H nuclear magnetic resonance spectroscopy of urine.	1998 Jun	9625050
L-lactic acid as a mosquito (Diptera: Culicidae) repellent on human and mouse skin.	2001 Jan	11268691
A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia.	2001 Jul	11446841
Asymmetric intramolecular [2 + 2] photocycloadditions: alpha- and beta-hydroxy acids as chiral tether groups.	2002 Feb 22	11846645
Asymmetric total synthesis of (+)-brefeldin A from (S)-lactate by triple chirality transfer process and nitrile oxide cycloaddition.	2002 Feb 8	11856018
1H and (13)C NMR spectroscopic analysis of human saliva.	2002 Jun	12097436
Synthesis of optically active atropisomeric anilide derivatives through diastereoselective N-allylation with a chiral Pd-pi-allyl catalyst.	2003 Dec 12	14656123
Structure of the O-polysaccharide of Proteus penneri 28 and Proteus vulgaris O31 and classification of P. penneri 26 and 28 in Proteus serogroup O31.	2003 Oct 24	14557001
Asymmetric intermolecular C-H functionalization of benzyl silyl ethers mediated by chiral auxiliary-based aryldiazoacetates and chiral dirhodium catalysts.	2005 Dec 23	16355994
Proton MR CSF analysis and a new software as predictors for the differentiation of meningitis in children.	2005 Jun	15627241
Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise.	2006 Jan	16324927
Non-Hodgkin's lymphomas: immunologic prognostic studies.	2007 Jul	17921917
Design of a "new motif" with beta-amino acids and alpha-aminoxy acids: synthesis of hybrid peptides with 12/10-helix.	2008 May 16	18416577
Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81.	2009 Jan 30	19047060
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.	2009 May 1	19307507
Characterization of a diverse secretome generated by the mouse preimplantation embryo in vitro.	2010 Jun 23	20569467
Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.	2013 Jun	23396314

Patents

Sample Use Guides

In Vivo Use Guide

Facial fat loss (lipoatrophy) Sculptra (Poly-L-lactic acid): Intradermal or SubQ: ~0.05-0.2 mL per individual injection depending on technique used; ~20 injections may be needed per cheek. Treatment should be individualized. Separate treatments by ≥2 weeks. Typical course involves 3-6 treatments. Supplemental injections may be needed. Do not overfill contour deficiency. For patients with severe facial fat loss, the average treatment requires ~1 vial per cheek area per treatment.

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:13:08 GMT 2023` Edited by `admin` on `Fri Dec 15 15:13:08 GMT 2023`
Record UNII	P2Y1C6M9PS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SODIUM LACTATE, L-

Common Name

English

SODIUM (S)-LACTATE SOLUTION

Common Name

English

SODIUM (S)-LACTATE SOLUTION [EP MONOGRAPH]

Common Name

English

SODIUM L-LACTATE [JAN]

Common Name

English

SODIUM L-LACTATE

Common Name

English

SODIUM-L-LACTATE

Common Name

English

Sodium L-lactate [WHO-DD]

Common Name

English

(S)-2-HYDROXYPROPANOIC ACID MONOSODIUM SALT

Common Name

English

SODIUM (S)-LACTATE

Systematic Name

English

SODIUM LACTATE, (S)-

Common Name

English

SODIUM LACTATE, L- [II]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29730